Advertisement

Picture Excelya CRO Your Trial Across Europe 650x80px
Financing › Details

Inovedis–SEVERAL: investment, 202106 seed financing round €1.8m led by HTGF

 

Period Period 2021-06-01
Organisations Money taker Inovedis GmbH
  Money source SEVERAL
Products Product implant
  Product 2 venture capital
Person Person Fichtner, Caroline (High-Tech Gründerfonds 201002 Senior Investment Manager)
     

High-Tech Gründerfonds Management GmbH. (6/1/21). "Press Release: Medtech Startup Inovedis Closes 7-digit Seed Financing Round". Albstadt.

The medical technology start-up Inovedis located in Albstadt has closed a financing round of EUR 1.8 million, led by High-Tech Gründerfonds. The fund invests together with MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg and Volksbank Albstadt ChancenKapital and a group of renowned angel investors. Inovedis is developing a new surgical technique for shoulder injuries based on a PEEK implant. The optimal treatment result is achieved through simple, fast and safe surgical technique.


The “rotator cuff” describes the muscle-tendon that is located around the shoulder joint. The rotator cuff rupture is by far the most frequent injury of the shoulder. The SINEFIX implant system allows refixation of the tendon with a simplified surgical technique and is optimized for minimally invasive surgery.

The technique is easy and quick to learn for the surgeon, minimizing complications due to surgical mistakes. As a result, in addition to improved results, significant time and cost reduction can be expected. In the most important markets, more than 5 million patients are surgically repaired at the rotator cuff every year. The patented SINEFIX system will be launched in the USA in 2023. In parallel the clinical study for the approval process in Europe will start.

»During the development phase we focused on keeping the operation as simple as possible while taking biology and biomechanics into account.«
Dr. med. Stefan Welte, inventor of SINEFIX and co-founder of Inovedis

»We are very proud to have been able to win High-Tech Gründerfonds as well as MBG and Volksbank Albstadt Chancen Kapital for our project. It takes enormous effort and a huge amount of capital to bring a medical product to market.«
Lukas Flöß, Founder and CEO

With the fresh capital, the product development of the patented SINEFIX implant will be completed and the market launch in the USA will be implemented.

»We were impressed by Inovedis’ concept of designing an implant that promises a better therapeutic outcome, whereas at the same time it fits into the established procedures of surgeons. In addition, we are impressed by the determination with which the Inovedis team is working on the development of SINEFIX.«
Dr. Caroline Fichtner, Principal at High-Tech Gründerfonds


Inovedis Founders

Lukas Flöß and Dr. med. Stefan Welte, Founders of Inovedis


About Inovedis GmbH

Inovedis GmbH, located in the start-up and networking center in Albstadt, has been founded in 2016. In 2019, the company started operations and began to develop the implant. Initial funding for Inovedis GmbH was financed by the Startup BW PreSeed and Startup BW Protect programs.

www.Inovedis.de

Media contact:
Inovedis GmbH
Lukas Flöß, CEO
An der Technologiewerkstatt 1, 72461, Albstadt
07432 13099 20
Lukas.Floess@Inovedis.de


About MBG

MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg GmbH is a private equity company investing in startups and entrepreneurs as lead and co-investor. With their promotional regional mandate their task is to improve the financing situation of start-ups and medium-sized enterprises in Baden-Württemberg. This creates the basis for a solid company development and further growth. Its current portfolio consists of approximately 760 investments of a total volume of 214 million euros.
www.mbg.de

Investor Contact:
MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg GmbH
Frank Kraheberger, Leiter VC Fonds
Tel.:+49 711 1645-772
frank.kraheberger@mbg.de


About Volksbank Albstadt ChancenKapital

The Volksbank Albstadt ChancenKapital is a company of the Volksbank Albstadt eG. The company supports the foundation of new companies with venture capital and the expansion of the equity base of existing companies with mezzanine capital. This makes Volksbank Albstadt eG the first bank in the district of Zollernalbkreis to support the local economy in our region in this close and cooperative partnership.

Kontakt Investor:
Volksbank Albstadt ChancenKapital GmbH
Markus Haug, Geschäftsführer
Tel.:+49 7431 576-151
markus.haug@volksbank-albstadt.de


About High-Tech Gründerfonds

High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 600 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 3 billion into the HTGF portfolio via more than 1,700 follow-on financing rounds. HTGF has also successfully sold interests in more than 120 companies.

Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Bank, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.
www.htgf.de/en

Media Contact:
High-Tech Gründerfonds Management GmbH
Stefanie Grüter, Head of Marketing & Communications
T.: +49 228 82300 188
s.grueter@htgf.de

Investor Contact:
High-Tech Gründerfonds Management GmbH
Dr. Caroline Fichtner, Principal/Prokurist
T.: +49 228 82300 113
c.fichtner@htgf.de

   
Record changed: 2021-06-06

Advertisement

Picture Excelya CRO Your Trial Across Europe 650x80px

More documents for Inovedis GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Excelya CRO We Care for Your Clinical Trials 650x80px




» top